{"name":"Michio Hirano, MD","slug":"michio-hirano-md","ticker":"","exchange":"","domain":"","description":"Michio Hirano, MD is a biotechnology company focused on the development of hematopoietic allogeneic stem cells, though its primary drug has been discontinued. The company operates in a niche area of regenerative medicine and has not disclosed detailed financial or operational information.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMijAFBVV95cUxOdWE2ZmxUV1pOdXp4TFJJbHJCZzFNUTFKamVWbGRHU3JER0FsUTk0Y2xDY1FFczMwdHdrYVh0VjJqcmx4VWk2dGVoZ1ZVUHpUTVNYd1dSR2k3WDVmZEo0QkdTLTRsZXFuMEhJUkpHWnF0Tm5neEQyYVcyakxScDQxakJHcWFkLTdHUmlEWA?oc=5","date":"2025-11-04","type":"regulatory","source":"Fierce Pharma","summary":"On a roll, UCB picks up another rare disease FDA approval - Fierce Pharma","headline":"On a roll, UCB picks up another rare disease FDA approval","sentiment":"positive"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}